NEW YORK, April 21, 2015 /PRNewswire/ -- Laidlaw & Co. (UK) Ltd., the New York based investment bank, today announced the expansion of its Institutional Equities distribution platform with the appointments of Kris Tomasulo as a Managing Director for Institutional Equity Sales and Robert Baumann as Head of Institutional Equity Trading. Kris and Bob will be joining the New York office. Laidlaw has also made two new senior capital market hires in Boston, bringing on Jim Molloy as a Managing Director covering Specialty Pharmaceuticals and Biotechnology stocks and Matt Dormer as a Managing Director in Investment Banking.
"We are continuing to invest in our capital markets business following a significant growth in our market share over the last 12 months, specifically in our core healthcare vertical. We are excited by the investments we have made, by broadening our distribution network and adding experience to our research and banking teams. We continue to move forward in client relevance in the healthcare investment landscape," said Matthew Eitner, Chief Executive Officer, Laidlaw & Co. (UK) Ltd.
Kris Tomasulo will join Laidlaw's Institutional Equity Sales team. He joins Laidlaw from Sterne Agee & Co., where he was most recently working with the healthcare team. Kris previously managed equity funds at Merus Capital Partners, Scoggin Capital, and The Galleon Group. At Galleon, Kris co-managed The Galleon Healthcare Fund, where he led an investment team of 5 professionals. Kris brings deep relationships in the healthcare financial community and will increase the penetration of Laidlaw's research and other product offerings in the market.
Bob Baumann will assume the role of Head of Institutional Equity Trading. Prior to Laidlaw, Bob ran the institutional sales and trading desk at Summer Street Research Partners. With his 18 years of experience, Bob brings extensive healthcare trading knowledge along with deep institutional buy-side relationships to Laidlaw. Bob began his career at Banc of America Securities and has worked at Goldman Sachs, Leerink Swann, and Sanford Bernstein, where he successfully built and ran their healthcare sector trading platform for eight years.
Jim Molloy brings over 15 years of sell-side experience to Laidlaw, having covered Specialty Pharmaceuticals and Biotechnology for a diverse group of Wall Street investment banks. Prior to Laidlaw, Jim was a Managing Director at Summer Street Research Partners and Janney Montgomery Scott. Prior to that he was a Senior Analyst at ThinkEquity Partners, Caris & Company, Oppenheimer, and Leerink Swann & Company. Jim has been ranked by Forbes Starmine for earnings accuracy.
Matt Dormer joins Laidlaw & Co. (UK) Ltd. from Summer Street Research Partners. During his time at Summer Street he completed more than 40 transactions which raised over $1.5 billion for biotechnology, medical device, and healthcare IT companies. Matt formerly worked for Wellington Management Company in the portfolio advisor group and previously worked in the equity research group covering the biotechnology sector at Fulcrum Global Partners in New York City. Prior to his experience in equity research, Matt was a scientist for a start-up biotechnology company and a research associate and teaching fellow at Harvard University, where he conducted research on tumor suppressor genes.
About Laidlaw & Co. (UK) Ltd.
Laidlaw & Co. (UK) Ltd., founded in 1842, is a relationship driven international investment bank, providing wealth management services, capital raising, mergers & acquisitions advisory, research and corporate access to clients on a global level. Headquartered in New York City and United Kingdom, Laidlaw maintains eight offices across the United States and London, England with over 200 employees firm wide. Laidlaw also offers personalized investment advice and skillful execution to private and public institutions, as well as high net worth individual investors. The firm is a FINRA, MSRB and SIPC registered company.
Laidlaw & Co. (UK) Ltd.
Phone : 212-953-4900
SOURCE Laidlaw & Co. (UK) Ltd.